- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Chemical engineers at the Massachusetts Institute of Technology have designed a new type of drug-delivery nanoparticle that exploits a trait shared by almost all tumors: They are more acidic than healthy tissues. Such particles could target nearly any type of tumor, and can be designed to carry virtually any type of drug, says Paula Hammond, a member of the MIT-Harvard Center of Cancer Nanotechnology Excellence and leader of the investigators who built these new nanoparticles. The results of their experiments were published in the journal ACS Nano.
Like most other drug-delivering nanoparticles, the new MIT particles are cloaked in a polymer layer that protects them from being degraded by the bloodstream. In this case, however, the MIT team designed that outer layer to fall off after entering the slightly more acidic environment near a tumor. Shedding that protective layers reveals another layer that is able to penetrate individual tumor cells.
The new MIT approach differs from that taken by most nanoparticle designers who typically try to target their particles to a tumor by decorating them with molecules that bind specifically to proteins found on the surface of cancer cells. The problem with that strategy is that it's difficult to find the right target, that is, a molecule found on all of the cancer cells in a particular tumor but not on healthy cells. In addition, a target that works for one type of cancer might not work for another, limiting the utility of the resulting drug. Instead, Dr. Hammond and her colleagues decided to take advantage of tumor acidity, which is a byproduct of a tumor's revved-up metabolism.
To build their targeted particles, the researchers used a technique called "layer-by-layer assembly." This means each layer can be tailored to perform a specific function. When the outer layer, made of polyethylene glycol, or PEG, breaks down in the tumor's acidic environment, a positively charged middle layer is revealed, one that helps the nanoparticle to breach the negatively charged cell membrane. The nanoparticles' innermost layer can be a polymer that carries a cancer drug, or a quantum dot that could be used for imaging, or virtually anything else that the designer might want to deliver, said Dr. Hammond. Other researchers have tried to design nanoparticles that take advantage of tumors' acidity, but Dr. Hammond's particles are the first that have been successfully tested in living animals.
About The National Cancer Institute (NCI)
The NCI Alliance for Nanotechnology in Cancer is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat, and prevent cancer. Through its programs and initiatives, the Alliance is committed to building a community of researchers dedicated to using nanotechnology to advance the fight against cancer.
As part of the Center for Strategic Scientific Initiatives, the Alliance for Nanotechnology in Cancer works in concert with other NCI advanced technology initiatives to provide the scientific foundation and team science that is required to transform cancer research and care.
For more information, please click here
National Cancer Institute
Center for Strategic Scientific Initiatives
ATTN: NCI Office of Cancer Nanotechnology Research (OCNR)
Building 31, Room 10A52
31 Center Drive, MSC 2580
Bethesda, MD 20892-2580
Telephone: (301) 451-8983
Copyright © The National Cancer Institute (NCI)If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016